Given that either loss-of-function point mutations or inactivation of SMARCA4 have been outlined in several hematological malignancies, targeting its paralog (SMARCA2) might be a potential therapeutic alternative for the treatment of these cancers. This evidence concerns the gene SMARCA2 and cancer.